{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:04:07Z","timestamp":1761393847537,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.jneuroim.2009.09.017","type":"journal-article","created":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T04:17:41Z","timestamp":1255580261000},"page":"90-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Managing non-paraneoplastic Lambert\u2013Eaton myasthenic syndrome: Clinical characteristics in 25 German patients"],"prefix":"10.1016","volume":"217","author":[{"given":"Hannah L.","family":"Pellkofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Linke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Schumm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Voltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2009.09.017_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/1531-8249(200007)48:1<105::AID-ANA16>3.0.CO;2-G","article-title":"[18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies","volume":"48","author":"Antoine","year":"2000","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2009.09.017_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0720-048X(96)01032-7","article-title":"Lung cancer staging: the role of computed tomography and magnetic resonance imaging","volume":"23","author":"Bonomo","year":"1996","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/j.jneuroim.2009.09.017_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/annonc\/mdl374","article-title":"A prospective study of PET\/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis","volume":"18","author":"Fischer","year":"2007","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jneuroim.2009.09.017_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2009.09.017_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jneuroim.2005.03.020","article-title":"Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes","volume":"165","author":"Graus","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.2007.118588","article-title":"Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: twenty-two newly diagnosed patients and review of previous cases","author":"Hoffmann","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jneuroim.2009.09.017_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.1966.tb45484.x","article-title":"Defects of neuromuscular transmission in syndromes other than myasthenia gravis","volume":"135","author":"Lambert","year":"1966","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.1971.tb30750.x","article-title":"Quantal components of end-plate potentials in the myasthenic syndrome","volume":"183","author":"Lambert","year":"1971","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.jneuroim.2009.09.017_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mus.880111105","article-title":"Selected IgG rapidly induces Lambert\u2013Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities","volume":"11","author":"Lambert","year":"1988","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2009.09.017_bib11","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert\u2013Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410290313","article-title":"Calcium channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"29","author":"Leys","year":"1991","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2009.09.017_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/01.WNL.0000129983.06983.4E","article-title":"Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis","volume":"63","author":"Linke","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2009.09.017_bib14","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1073\/pnas.86.5.1689","article-title":"Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison","volume":"86","author":"Llin\u00e1s","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.jneuroim.2009.09.017_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","article-title":"Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer","volume":"70","author":"Maddison","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3A","key":"10.1016\/j.jneuroim.2009.09.017_bib15","first-page":"1773","article-title":"Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer","volume":"25","author":"Molina","year":"2005","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.jneuroim.2009.09.017_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jneuroim.2009.09.017_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert\u2013Eaton myasthenic syndrome","volume":"32","author":"Oh","year":"2005","journal-title":"Muscle Nerve"},{"issue":"Pt 3","key":"10.1016\/j.jneuroim.2009.09.017_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert\u2013Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O'Neill","year":"1988","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jneuroim.2009.09.017_bib19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0198-8859(00)00135-X","article-title":"Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert\u2013Eaton myasthenic syndrome without associated cancer","volume":"61","author":"Parsons","year":"2000","journal-title":"Hum. Immunol."},{"issue":"9384","key":"10.1016\/j.jneuroim.2009.09.017_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(03)14188-8","article-title":"Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results","volume":"362","author":"Pastorino","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2009.09.017_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2008.08.002","article-title":"Lambert\u2013Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel","author":"Pellkofer","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2009.09.017_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mus.21315","article-title":"Favorable response to rituximab in a patient with anti-VGCC-positive Lambert\u2013Eaton myasthenic syndrome and cerebellar dysfunction","volume":"40","author":"Pellkofer","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2009.09.017_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00259-006-0186-3","article-title":"Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET\/CT protocols for staging and therapy planning in non-small cell lung cancer","volume":"34","author":"Pfannenberg","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.jneuroim.2009.09.017_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jso.2930340405","article-title":"Myasthenic syndrome (Eaton\u2013Lambert syndrome) associated with pulmonary adenocarcinoma","volume":"34","author":"Ramos-Yeo","year":"1987","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/124.11.2223","article-title":"The role of [18F]fluoro-2-deoxyglucose-FDG-PET scanning in the diagnosis of paraneoplastic neurological disorders","author":"Rees","year":"2001","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.jneuroim.2009.09.017_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert\u2013Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2009.09.017_bib27","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/ana.410370708","article-title":"Lambert\u2013Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies","volume":"37","author":"Sanders","year":"1995","journal-title":"Ann. Neurol."},{"issue":"Pt 4","key":"10.1016\/j.jneuroim.2009.09.017_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/brain\/121.4.561","article-title":"The cerebellar cognitive affective syndrome","volume":"121","author":"Schmahmann","year":"1998","journal-title":"Brain"},{"issue":"2A","key":"10.1016\/j.jneuroim.2009.09.017_bib29","first-page":"885","article-title":"Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases","volume":"23","author":"Schneider","year":"2003","journal-title":"Anticancer Res."},{"issue":"4A","key":"10.1016\/j.jneuroim.2009.09.017_bib30","first-page":"2673","article-title":"Pro-gastrin-releasing peptide (ProGRP)\u2014\u2014a useful marker in small cell lung carcinomas","volume":"19","author":"Stieber","year":"1999","journal-title":"Anticancer Res."},{"issue":"6451","key":"10.1016\/j.jneuroim.2009.09.017_bib31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/366156a0","article-title":"Different types of calcium channels mediate central synaptic transmission","volume":"366","author":"Takahashi","year":"1993","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jneuroim.2009.09.017_bib32","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.54.11.2176","article-title":"Lambert\u2013Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment","volume":"54","author":"Tim","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.09.017_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2008.05.025","article-title":"The Lambert\u2013Eaton myasthenic syndrome 1988\u20132008: a clinical picture in 97 patients","author":"Titulaer","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"26","key":"10.1016\/j.jneuroim.2009.09.017_bib34","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","article-title":"Screening for small-cell lung cancer: a follow-up study of patients with Lambert\u2013Eaton myasthenic syndrome","volume":"26","author":"Titulaer","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jneuroim.2008.06.031","article-title":"Calcium channels, neuromuscular synaptic transmission and neurological diseases","volume":"201\u2013202","author":"Urbano","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0166-2236(89)90109-4","article-title":"Autoimmunity to the voltage-gated calcium channels underlies the Lambert\u2013Eaton myasthenic syndrome, a paraneoplastic disorder","volume":"12","author":"Vincent","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/01.WNL.0000130254.27019.14","article-title":"The epidemiology of the Lambert Eaton myasthenic syndrome in the Netherlands","volume":"63","author":"Wirtz","year":"2004","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2009.09.017_bib38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","article-title":"HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert\u2013Eaton myasthenic syndrome","volume":"159","author":"Wirtz","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.09.017_bib39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mus.20332","article-title":"Lambert\u2013Eaton myasthenic syndrome has a more progressive course in patients with lung cancer","volume":"32","author":"Wirtz","year":"2005","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572809003853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572809003853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:12:45Z","timestamp":1759047165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572809003853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":39,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0165572809003853"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2009.09.017","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing non-paraneoplastic Lambert\u2013Eaton myasthenic syndrome: Clinical characteristics in 25 German patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2009.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}